Literature DB >> 24751729

Next-generation sequencing of nevus spilus-type congenital melanocytic nevus: exquisite genotype-phenotype correlation in mosaic RASopathies.

Veronica A Kinsler1, Sven Krengel2, Jean-Baptiste Riviere3, Regula Waelchli4, Carolina Chapusot5, Lara Al-Olabi6, Laurence Faivre7, Holger A Haenssle8, Lisa Weibel9, Géraldine Jeudy7, Pierre Vabres10.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24751729      PMCID: PMC4165863          DOI: 10.1038/jid.2014.195

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


× No keyword cloud information.
TO THE EDITOR Nevus spilus is a descriptive term used to denote any cutaneous lesion with a café-au-lait macular background and superimposed on more pigmented areas. Small single nevus spilus are relatively common, and they have recently been described to be due to somatic activating HRAS mutations (Sarin ). Larger superficial lesions with small superimposed junctional nevi in association with phakomatosis pigmentokeratotica have also been found to contain HRAS mutations (Groesser ). However, another nevus spilus–type phenotype has also been well described in which large café-au-lait macules have superimposed lesions that are indistinguishable both clinically and histopathologically from medium/large congenital melanocytic nevi (CMN), exhibit a wide variety of colors and sizes (Schaffer , 2001b), and continue to develop postnatally in many cases. This is termed nevus spilus–type CMN. In our experience, there may be delayed appearance of the café-au-lait background after birth, but the lesion is still usually predictable on the basis of clustering of many CMN in one anatomical area. Smaller separate lesions in the same individual are often indistinguishable clinically from café-au-lait macules, and are so faint that they can be easily missed (Figure 1). Our primary aim in this study was to look for the genetic basis of this defined phenotypic subset of CMN, in the context of the recent discovery that NRAS Q61K and Q61R mutations are the cause of most causes of multiple CMN (Kinsler ). In particular, we were interested in determining the mutation in the background macular portion of the nevus spilus–type CMN, working on the hypothesis that this could be the “first hit” in a two-hit model of nevogenesis.
Figure 1

Clinical images of nevus spilus–type CMN in six different patients. The café-au-lait macule background is often invisible at birth. Two separate lesions are indicated in one patient. CMN, congenital melanocytic nevi. Written consent was obtained for publication of all photographs.

These studies were approved by the appropriate Research Ethics Committee, written consent was taken from participants, and the Declaration of Helsinki Principles protocols were followed. A blood sample and skin biopsies of both the café-au-lait macule background and a banal superimposed CMN were taken from three children with large nevus spilus–type CMN, from a total of 17 patients from our combined practices (patients 5, 12, and 13 in Supplementary Table S1 online), and DNA was extracted directly by standard methods. Whole-exome sequencing using Nextera library preparation and an ABI Hi-Seq bioanalyser was undertaken on all three samples from two patients, and data were analyzed using an in-house pipeline designed for somatic mosaicism. The principal governing analysis was to look for a mutation present in the café-au-lait that was not present in the blood, and a further mutation in the CMN not present in the café-au-lait or the blood. In all, 1,991,478 variants were called automatically in the overlying CMN, affecting 20,693 genes. After filtering, the sequencing files of 133 variants in 39 genes were reviewed manually. A single mutation was found in the café-au-lait macule and the superimposed CMN, with no further mutation confirmed despite extensive analysis. These mutations were missense activating mutations in NRAS in the skin, absent from the blood, and this pattern of somatic mosaicism was confirmed in the third patient by Sanger sequencing. The mutations, however, are undescribed so far in typical CMN, being 1:115256528 c.183A>C p.Q61H (two patients, Figure 2) and 1:115258745 c.37G>C p.G13R. Both mutations have been described at a somatic level in non-CMN-related malignant melanoma (Forbes ). Independently, a fourth patient (patient 17, Supplementary Table S1 online) had targeted exon capture of two skin samples, and analysis also revealed only the same NRAS p.Q61H mutation in both the café-au-lait macule and the superimposed CMN.
Figure 2

Sequencing results showing Next-generation sequencing reads of blood (upper left), café-au-lait macule (upper centre), and overlying CMN (upper right) from the same patient showing mutation NRAS c.183A>C p.Q61H. Note the absence of mutation in the blood, and the much lower percentage of mosaicism in the café-au-lait than the CMN, as would be expected from the number of affected cells in a biopsy sample. Sanger sequencing (below) confirmation of the heterozygous pQ61H mutation in CMN. CMN, congenital melanocytic nevi.

In conclusion, nevus spilus–type CMN are a phenotypically and genotypically distinct variant of CMN, and are phenotypically and genotypically distinct from nevus spilus maculosus and papulosus due to HRAS mutations (Groesser ; Sarin ). This further extends the exquisite mutation specificity of the newly characterized mosaic RASopathies. We found no evidence of a second mutation to explain the superimposed nevi on the macular background. It is, however, possible that there could be a mutation that does not appear pathogenic to us and to the analysis pipelines at the present time. Alternatively, there could be either a translocation that does not disrupt exonic DNA sequence, or a growth-promoting copy number change, although CMN have previously been documented as having few such changes on array comparative genomic hybridization (Bastian ). The data at the moment suggest that only one sequence-level mutation occurs, and that these specific NRAS mutations are sufficient to cause café-au-lait macular pigmentation, which can lead to macroscopic nevus formation over time. Other experimental evidence supports that nevi can evolve in this way, from a cell or collection of cells in the skin not visible to the naked eye, as nevus cells have been found in normal skin in patients with acquired melanocytic nevi and typical CMN (Dadzie ; Kinsler ). It is important to note for clinical management that malignant melanoma has been described in patients with nevus spilus–type CMN (Kinsler ), and on current knowledge we would consider nevus spilus–type CMN patients at the same risk of malignancy as other genotypes. Similarly, although interestingly none of the 17 patients described here have neurological abnormalities on magnetic resonance imaging scan (Supplementary Table S1 online), these numbers are too small to draw any conclusions about a possible low risk of neurological phenotype. Management of nevus spilus–type CMN should therefore be the same as for other CMN.
  11 in total

Review 1.  Speckled lentiginous nevus: within the spectrum of congenital melanocytic nevi.

Authors:  J V Schaffer; S J Orlow; R Lazova; J L Bolognia
Journal:  Arch Dermatol       Date:  2001-02

2.  Speckled lentiginous nevus--classic congenital melanocytic nevus hybrid not the result of "collision".

Authors:  J V Schaffer; S J Orlow; R Lazova; J L Bolognia
Journal:  Arch Dermatol       Date:  2001-12

3.  Incidental microscopic foci of nevic aggregates in skin.

Authors:  Ophelia E Dadzie; Ryan Goerig; Jag Bhawan
Journal:  Am J Dermatopathol       Date:  2008-02       Impact factor: 1.533

4.  Activating HRAS mutation in nevus spilus.

Authors:  Kavita Y Sarin; Jennifer M McNiff; Shirley Kwok; Jinah Kim; Paul A Khavari
Journal:  J Invest Dermatol       Date:  2014-01-03       Impact factor: 8.551

5.  Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus.

Authors:  Kavita Y Sarin; Bryan K Sun; Charles D Bangs; Athena Cherry; Susan M Swetter; Jinah Kim; Paul A Khavari
Journal:  JAMA Dermatol       Date:  2013-09       Impact factor: 10.282

6.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

7.  Great Ormond Street Hospital for Children Registry for congenital melanocytic naevi: prospective study 1988-2007. Part 1-epidemiology, phenotype and outcomes.

Authors:  V A Kinsler; J Birley; D J Atherton
Journal:  Br J Dermatol       Date:  2008-10-22       Impact factor: 9.302

8.  Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.

Authors:  Leopold Groesser; Eva Herschberger; Ana Sagrera; Tor Shwayder; Katharina Flux; Laura Ehmann; Andreas Wollenberg; Antonio Torrelo; Lorea Bagazgoitia; Blanca Diaz-Ley; Sigrid Tinschert; Ilske Oschlies; Sebastian Singer; Marion Mickler; Agusti Toll; Michael Landthaler; Francisco X Real; Christian Hafner
Journal:  J Invest Dermatol       Date:  2013-01-21       Impact factor: 8.551

9.  Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

Authors:  Veronica A Kinsler; Anna C Thomas; Miho Ishida; Neil W Bulstrode; Sam Loughlin; Sandra Hing; Jane Chalker; Kathryn McKenzie; Sayeda Abu-Amero; Olga Slater; Estelle Chanudet; Rodger Palmer; Deborah Morrogh; Philip Stanier; Eugene Healy; Neil J Sebire; Gudrun E Moore
Journal:  J Invest Dermatol       Date:  2013-02-07       Impact factor: 8.551

10.  Immunohistochemical and ultrastructural features of congenital melanocytic naevus cells support a stem-cell phenotype.

Authors:  V A Kinsler; G Anderson; B Latimer; D Natarajan; E Healy; G E Moore; N J Sebire
Journal:  Br J Dermatol       Date:  2013-08       Impact factor: 9.302

View more
  8 in total

1.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

2.  [Nevus spilus: An example of mosaic RASopathy].

Authors:  C Hafner
Journal:  Hautarzt       Date:  2015-05       Impact factor: 0.751

3.  Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies.

Authors:  Su Luo; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2014-10       Impact factor: 8.551

4.  Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus.

Authors:  Caitlin Porubsky; Jamie K Teer; Yonghong Zhang; Maria Deschaine; Vernon K Sondak; Jane L Messina
Journal:  J Cutan Pathol       Date:  2017-12-17       Impact factor: 1.587

5.  Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling.

Authors:  Jeffrey S Pawlikowski; Claire Brock; Sheau-Chiann Chen; Lara Al-Olabi; Colin Nixon; Fiona McGregor; Simon Paine; Estelle Chanudet; Wendy Lambie; William M Holmes; James M Mullin; Ann Richmond; Hong Wu; Karen Blyth; Ayala King; Veronica A Kinsler; Peter D Adams
Journal:  J Invest Dermatol       Date:  2015-03-27       Impact factor: 8.551

6.  The patterns of birthmarks suggest a novel population of melanocyte precursors arising around the time of gastrulation.

Authors:  Veronica A Kinsler; Lionel Larue
Journal:  Pigment Cell Melanoma Res       Date:  2017-10-13       Impact factor: 4.693

Review 7.  Melanoma in congenital melanocytic naevi.

Authors:  V A Kinsler; P O'Hare; N Bulstrode; J E Calonje; W K Chong; D Hargrave; T Jacques; D Lomas; N J Sebire; O Slater
Journal:  Br J Dermatol       Date:  2017-04-04       Impact factor: 9.302

8.  Does the gene matter? Genotype-phenotype and genotype-outcome associations in congenital melanocytic naevi.

Authors:  S Polubothu; N McGuire; L Al-Olabi; W Baird; N Bulstrode; J Chalker; D Josifova; D Lomas; J O'Hara; J Ong; D Rampling; P Stadnik; A Thomas; E Wedgeworth; N J Sebire; V A Kinsler
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.